Elevated ribonucleotide reductase levels associate with suppressed radiochemotherapy response in human cervical cancers

International Journal of Gynecological Cancer

Volumn 22, Issue 9, 2012, Pages 1463-1469

  Kunos, Charles A ^a   Radivoyevitch, Tomas ^a   Kresak, Adam ^a   Dawson, Dawn ^a   Jacobberger, James ^a   Yang, Bin ^b   Abdul Karim, Fadi W ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cervical cancer; Radiosensitivity; Ribonucleotide reductase

Indexed keywords

CISPLATIN; RIBONUCLEOTIDE REDUCTASE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHEMOSENSITIVITY; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE FREE SURVIVAL; ENZYME BLOOD LEVEL; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RESPONSE EVALUATION CRITERIA IN SOLID TUMOR; TISSUE MICROARRAY; TREATMENT RESPONSE; TUMOR VOLUME; UTERINE CERVIX CANCER;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; FEMALE; HUMANS; HYSTERECTOMY; MIDDLE AGED; RADIATION TOLERANCE; RIBONUCLEOTIDE REDUCTASES; TISSUE ARRAY ANALYSIS; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; UTERINE CERVICAL NEOPLASMS;

EID: 84872288212     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318270577f     Document Type: Article

References (25)

1. Kunos C. Therapeutic mechanisms of treatment in cervical and vaginal cancer. Oncol Hematol Rev. 2012;8:55-60.
2. Hebner C, Laimins L. Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Rev Med Virol. 2006;16:83-97.
3. Kunos C, Chiu S, Pink J, Kinsella T. Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein. Radiat Res. 2009;172:666-676.
4. Kunos C, Radivoyevitch T, Pink J, et al. Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers. Radiat Res. 2010;174:574-581.
5. Kunos C, Colussi V, Pink J, et al. Radiosensitization of human cervical cancer cells by inhibiting ribonucleotide reductase: enhanced radiation response at low dose rates. Int J Radiat Oncol Biol Phys. 2011;80:1198-1204.
6. Kunos C, Ferris G, Pyatka N, et al. Deoxynucleoside salvage facilitates DNA repair during ribonucleotide reductase blockade in human cervical cancers. Radiat Res. 2011;176:425-433.
7. Kuo M-L, Kinsella T. Expression of ribonucleotide reductase after ionizing radiation in human cervical carcinoma cells. Cancer Res. 1998;58:2245-2252.
8. Rofougaran R, Vodnala M, Hofer A. Enzymatically active mammalian ribonucleotide reductase exists primarily as an alpha6beta2 octamer. J Biol Chem. 2006;281:27705-27711.
9. Fairman J, Wijerathna S, Ahmad M, et al. Structural basis for allosteric regulation of human ribonucleotide reductase by nucleotide-induced oligomerization. Nat Struct Mol Biol. 2011;18:316-322.
10. Reece S, Hodgkiss J, Stubbe J, et al. Proton-coupled electron transfer: the mechanistic underpinning for radical transport and catalysis in biology. Philos Trans R Soc B Lond B Biol Sci. 2006;361:1351-1364.
11. Chabes A, Thelander L. Controlled protein degradation regulates ribonucleotide reductase activity in proliferating mammalian cells during the normal cell cycle and in response to DNA damage and replication blocks. J Biol Chem. 2000;275:17747-17753.
12. Tanaka H, Arakawa H, Yamaguchi T, et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature. 2000;404:42-49.
13. Kimura T, Takeda S, Sagiya Y, et al. Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools. Nat Genet. 2003;34:440-445.
14. Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 2007;356:800-808.
15. Morikawa T, Hino R, Uozaki H, et al. Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro. Hum Pathol. 2010;41:1742-1748.
16. Mann G, Musgrove E, Fox R, et al. Ribonucleotide reductase M1 subunit in cellular proliferation, quiescence, and differentiation. Cancer Res. 1988;48:5151-5156.
17. Feder J, Guidos C, Kusler B, et al. A cell cycle analysis of growth-related genes expressed during T lymphocyte maturation. J Cell Biol. 1990;111:2693-2701.
18. Pontarin G, Ferraro P, Rampazzo C, et al. Deoxyribonucleotide metabolism in cycling and resting human fibroblasts with a missense mutation in p53R2, a subunit of ribonucleotide reductase. J Biol Chem. 2011;286:11132-11140.
19. Pontarin G, Fijolek A, Pizzo P, et al. Ribonucleotide reduction is a cytosolic process in mammalian cells independently of DNA damage. Proc Natl Acad Sci U S A. 2008;105:17801-17806.
20. Kunos C, Waggoner S, Von Gruenigen V, et al. Phase I trial of intravenous 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in combination with pelvic radiation therapy and weekly cisplatin chemotherapy for locally advanced cervical cancer. Clin Cancer Res. 2010;16:1298-1306.
21. Kunos C, Radivoyevitch T, Abdul-Karim F, et al. 18F-fluoro-2-deoxy-d- glucose positron emission tomography standard uptake value as an indicator of cervical cancer chemoradiation therapeutic response. Int J Gynecol Cancer. 2011;21:1117-1123.
22. Hakansson P, Hofer A, Thelander L. Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells. J Biol Chem. 2006;281:7834-7841.
23. Xue L, Zhou B, Liu X, et al. Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits. Cancer Res. 2003;63:980-986.
24. Kunos C, Ali S, Abdul-Karim F, et al. Posttherapy residual disease associates with long-term survival after chemoradiation for bulky stage 1B cervical carcinoma: a Gynecologic Oncology Group Study. Am J Obstet Gynecol. 2010;203:e1-e8.
25. Bordeaux J, Welsh A, Agarwal S, et al. Antibody validation. Biotechniques. 2010;48:197-209.